PD-1 Fatigue: Cross-Labeling May Help Pare Checkpoint Inhibitor Pipeline
US FDA encouraging developers to embrace cross-labeling rather than continue separate development of proprietary PD-1 agents, but agency sounds eager for any other good ideas to pare back the number of checkpoint inhibitors in development.
